QR Code

A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants

Objectives: Safety and immunogenicity evaluation of a 4-dose series with 20-valent pneumococcal conjugate vaccine (PCV20). Methods: This phase 3, double-blind study randomized healthy Japanese infants to receive 4 doses (3 infant doses, 1 toddler dose) of PCV20 by subcutaneous (SC) or intramuscular...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Yasunori Ishihara, Mitsuru Fukazawa, Shinya Enomoto, Richard de Solom, Masako Yamaji, Mary Kline, Masakazu Aizawa, Yahong Peng, Osamu Kogawara, Peter C. Giardina, Noor Tamimi, William C. Gruber, Wendy Watson
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2024-04-01
Rangatū:International Journal of Infectious Diseases
Ngā marau:
20-valent pneumococcal conjugate vaccine
Immunogenicity
Infants
Safety
Japan
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S1201971224000109
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite